Previously, Moderna projected $2.5 billion to $3.5 billion in sales for that year. William Blair analyst Myles Minter called Moderna stock a "show-me story." Leerink Partners analyst Mani Foroohar ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new ...

The drop was tied in part to Moderna’s news that it was lowering its 2025 revenue guidance down to between $1.5 billion to $2.5 billion. The company had said back in its September R&D Day to ...

Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion ...